Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Inclusion Criteria: * Confirmed diagnosis of congenital haemophilia A or B with a FVIII:C clot activity or FIX:C clot activity, respectively, less than 5% * Presently use of activated recombinant human factor VII (NovoSeven®) as haemostatic agent for preventive treatment or treatment of bleeding episodes * A documented historical or present record for the presence of inhibitors to factor VIII or IX, respectively * A documented history of 2 or more joint bleeding episodes during the preceding 12 months * Subjects must be in a non-bleeding state (i.e. no clinical manifestations of active bleeds) Exclusion Criteria: * Subjects who have received any haemostatic treatment for a bleeding episode within the last 7 days prior to this trial * Immune tolerance therapy within the last 30 days prior to this trial * Clinically relevant coagulation disorders other than congenital haemophilia A or B * Thrombocytopenia (platelet count below 60,000 platelets/mcl) * Prophylactic haemostatic treatment within 3 days prior to this trial